Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ARIA > SEC Filings for ARIA > Form 8-K on 2-Jul-2013All Recent SEC Filings

Show all filings for ARIAD PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for ARIAD PHARMACEUTICALS INC


2-Jul-2013

Other Events, Financial Statements and Exhibits


ITEM 8.01 Other Events.

On July 2, 2013, ARIAD Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the European Commission (EC) has granted a marketing authorization for IclusigŪ (ponatinib) as an orphan medicinal product for two indications:

? The treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, and
? The treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.



ITEM 9.01 Financial Statements and Exhibits

(d) The following exhibit is filed with this report:

Exhibit
Number  Description

99.1    Press Release dated July 2, 2013.


  Add ARIA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ARIA - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.